Pancreatic Cancer Research

ResearcherKanazawa UniversityNo recent work listed

Toshifumi Gabata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9413-3431; OpenAlex author ID A5091741174. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper

Papers 8

  1. CT-diagnosed extra-pancreatic extension of pancreatic ductal adenocarcinoma is a more reliable prognostic factor for survival than pathology-diagnosed extensio… Last author DOI 10.1007/s00330-021-08180-6↗
  2. CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-C… Last author DOI 10.2214/ajr.21.26014↗
  3. Qualitative and quantitative evaluation for morphological changes of the splenic artery in autoimmune pancreatitis: novel imaging findings for differentiation … Last author DOI 10.1007/s00261-018-1634-9↗
  4. Multicenter study of early pancreatic cancer in Japan. Co-author DOI 10.1016/j.pan.2017.11.007↗
  5. [CT and MR imaging of pancreatic cancer]. Co-author PMID 25856986↗
  6. Hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases f… Co-author DOI 10.3892/mco.2013.152↗
  7. [Hepatic arterial infusion chemotherapy with gemcitabine for patients with postoperative liver metastases from pancreatic cancer]. Co-author PMID 24393883↗
  8. Pilot study of hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for patients with postoperative liver metastases from pancreatic canc… Co-author DOI 10.3892/etm.2011.190↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dai Inoue · 3 shared papers, 2018–2022 · strength 0.38
  2. Fumihito Toshima · 3 shared papers, 2018–2022 · strength 0.38
  3. Takashi Sasaki · 1 shared paper, 2021 · strength 0.12
  4. Masato Matsuyama · 1 shared paper, 2021 · strength 0.12
  5. Naoki Sasahira · 1 shared paper, 2021 · strength 0.12
  6. Satoshi Kobayashi · 1 shared paper, 2018 · strength 0.08
  7. Isamu Makino · 3 shared papers, 2011–2013 · strength 0.07
  8. Tetsuo Ohta · 3 shared papers, 2011–2013 · strength 0.07
  9. Hidehiro Tajima · 3 shared papers, 2011–2013 · strength 0.07
  10. Atsushi Kanno · 1 shared paper, 2018 · strength 0.06
  11. Mamoru Takenaka · 1 shared paper, 2018 · strength 0.06
  12. Masafumi Nakamura · 1 shared paper, 2018 · strength 0.06
  13. Tooru Shimosegawa · 1 shared paper, 2018 · strength 0.06
  14. Takao Ohtsuka · 1 shared paper, 2018 · strength 0.06
  15. Keiji Hanada · 1 shared paper, 2018 · strength 0.06
  16. Atsushi Masamune · 1 shared paper, 2018 · strength 0.06
  17. Akio Yanagisawa · 1 shared paper, 2018 · strength 0.06
  18. Koji Yoshida · 1 shared paper, 2018 · strength 0.06
  19. Toru Furukawa · 1 shared paper, 2018 · strength 0.06
  20. Masataka Kikuyama · 1 shared paper, 2018 · strength 0.06
  21. Masayuki Kitano · 1 shared paper, 2018 · strength 0.06
  22. Tomoharu Miyashita · 2 shared papers, 2013 · strength 0.05
  23. Yoshimichi Sai · 2 shared papers, 2013 · strength 0.05
  24. Itasu Ninomiya · 2 shared papers, 2011–2013 · strength 0.04
  25. Osamu Matsui · 2 shared papers, 2011–2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.